SUM52PEHomo sapiens (Human)Cancer cell line
Also known as: 52PE, SUM52, SUM 52, SUM-52, SUM-52-PE, SUM 52PE, SUM-52PE
Quick Overview
SUM52PE is a breast cancer cell line derived from pleural effusion, used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_3425 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Pleural effusion[UBERON:UBERON_0000175] |
Donor Information
| Age Category | Unknown |
|---|---|
| Sex | Female |
| Subtype Features | luminal TNBC |
Disease Information
| Disease | Breast carcinoma |
|---|---|
| Lineage | Breast |
| Subtype | Invasive Breast Carcinoma |
| OncoTree Code | BRCA |
DepMap Information
| Source Type | Asterand |
|---|---|
| Source ID | ACH-001396_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Arg213Ter (c.637C>T) | Unspecified | - | Unknown |
| MutationSimple | CDKN2A | p.Ala68Val (c.203C>T) | Homozygous | - | from parent cell line SUM52PE |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Development and implementation of the SUM breast cancer cell line functional genomics knowledge base.
Duchinski K., Couch D., Gray J.W., Kappler C.S.
NPJ Breast Cancer 6:30.1-30.14(2020).
Activating mutations in PIK3CB confer resistance to PI3K inhibition and define a novel oncogenic role for p110beta.
Hampton G.M., Lackner M.R.
Cancer Res. 76:1193-1203(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Modeling precision treatment of breast cancer.";
Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Genome Biol. 14:R110.1-R110.14(2013).
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Martens J.W.M.
Breast Cancer Res. 15:R33.1-R33.17(2013).
Phenotypic and molecular characterization of MCF10DCIS and SUM breast cancer cell lines.
Barnabas N., Cohen D.
Int. J. Breast Cancer 2013:872743.1-872743.16(2013).
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
Chavez K.J., Garimella S.V., Lipkowitz S.
Breast Dis. 32:35-48(2010).
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Breast Cancer Res. Treat. 121:53-64(2010).
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Pollack J.R.
PLoS ONE 4:E6146-E6146(2009).
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
Cancer Cell 10:515-527(2006).
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Breast Cancer Res. Treat. 99:97-101(2006).
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.
Cancer Res. 66:41-45(2006).
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Edwards P.A.W., Caldas C.
Carcinogenesis 26:923-930(2005).
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Edwards P.A.W., Chaffanet M.
Genes Chromosomes Cancer 37:333-345(2003).
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.
Cancer Res. 60:4519-4525(2000).
Molecular cytogenetic analysis of 11 new breast cancer cell lines.";
Kallioniemi O.-P., Ethier S.P.
Br. J. Cancer 81:1328-1334(1999).